BioTuesdays

Soricimed to present four posters at AACR

Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20.

The presentations are based on preclinical and clinical research conducted on the company’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel.

In February, the company announced positive top-line results from a Phase 1 trial with SOR-C13 in patients with advanced solid tumors, including lung, colon, breast and prostate cancers. Preliminary data demonstrated safety and tolerability in patients, as well as potential activity, with 54% of patients achieving stable disease.

The company’s presentations at AACR will include data demonstrating the anti-tumor targeting potential for the SOR-C series peptides, specifically targeting the TRPV6 calcium channel, a novel target in oncology, which is highly elevated in solid tumors. Phase 1 clinical trial results from SOR-C13 also showed the potential of targeting TRPV6 in advanced adenocarcinomas of the pancreas.

Soricimed’s collaborators will be presenting preclinical data on SOR-C13 in an additional poster, suggesting a novel therapeutic approach for multiple myeloma, involving TRPV6 inhibition to target both myeloma cells and osteoclasts.

Subscribe

Sign up to our weekly BioTuesdays newsletter.

Subscribe

Sign up to our weekly BioTuesdays newsletter.